InMode beat Q2 earnings expectations by $0.02 per share and topped revenue estimates on steady U.S. demand for its RF microneedling and radiofrequency platforms. The company's core U.S. installed base continues to drive recurring revenue and procedure volume.
Devices & Tech
InMode Q2 Beats on Steady U.S. Device Demand
Earnings topped estimates; U.S. market holding despite competitive RF microneedling saturation.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
U.S. RF microneedling demand remains steady despite growing competitive saturation.
For practice owners, InMode's resilience reflects the durability of RF microneedling as a workhorse modality—high patient demand, strong per-treatment margins, and minimal reimbursement friction. However, the competitive field (Cutera, Lumenis, Candela) has densified, and device acquisition cost and break-even patient volume remain critical variables. If you're evaluating an RF platform acquisition or lease, benchmark InMode's installed-base economics against newer entrants offering lower capex or faster ROI.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.